Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
Year: 2008
Type: article
Study design: Clinical Trial
Source: Lung Cancer
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
OpenAlex ID: W2017749679
